Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

27.69USD
4:00pm EDT
Change (% chg)

$0.54 (+1.99%)
Prev Close
$27.15
Open
$27.29
Day's High
$27.84
Day's Low
$26.88
Volume
259,442
Avg. Vol
398,538
52-wk High
$56.66
52-wk Low
$24.63

Chart for

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $1,794.22
Shares Outstanding(Mil.): 66.09
Dividend: --
Yield (%): --

Financials

  PTLA.OQ Industry Sector
P/E (TTM): -- 109.17 32.55
EPS (TTM): -5.71 -- --
ROI: -106.67 1.47 12.80
ROE: -222.14 0.22 14.92

BRIEF-Portola Pharmaceuticals Receives $100 Mln Milestone Payment From Healthcare Royalty Partners For FDA Approval Of Andexxa

* PORTOLA PHARMACEUTICALS RECEIVES $100 MILLION MILESTONE PAYMENT FROM HEALTHCARE ROYALTY PARTNERS FOR FDA APPROVAL OF ANDEXXA® Source text for Eikon: Further company coverage:

May 24 2018

BRIEF-Portola Pharmaceuticals Q1 Loss Per Share $1.28

* PORTOLA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-U.S. FDA Approves Portola Pharmaceuticals’ Andexxa

* U.S. FDA APPROVES PORTOLA PHARMACEUTICALS’ ANDEXXA®, FIRST AND ONLY ANTIDOTE FOR THE REVERSAL OF FACTOR XA INHIBITORS

May 03 2018

Competitors

Earnings vs. Estimates